

CERTIFICATE

Survey of 25 May 2018

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Haemostasis 13 - LMW Heparin (281):

Validity 12 months:

Low mol. weight Heparin

Haemostasis 22 - Dabigatran (502):

Validity 12 months:

Dabigatran

Haemostasis 23 - Rivaroxaban (503):

Validity 12 months:

Rivaroxaban

Haemostasis 25 - Apixaban (504):

Validity 12 months:

Apixaban

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr., PhD. Martin Spacek

Vseobecná fakultní nemocnice v Praze

Centrální hematologické laboratorie ULBLD

U Nemocnice 2

12808 Praha 2



Düsseldorf, 30 July 2018

Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)

Prof. Dr. med. Dirk Peetz
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 25 May 2018

You have participated in the External Quality Assessment with the following analysis

Haemostasis 13 - LMW Heparin (281):

Low mol. weight Heparin

Haemostasis 22 - Dabigatran (502):

Dabigatran

Haemostasis 23 - Rivaroxaban (503):

Rivaroxaban

Haemostasis 25 - Apixaban (504):

Apixaban

(R) analysis is subject to the RiliBÄK

Participant:

2430

MUDr., PhD. Martin Spacek


Vseobecná fakultní nemocnice v Praze

Centrální hematologické laboratorie ULBLD

U Nemocnice 2

12808 Praha 2

Düsseldorf, 30 July 2018



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Prof. Dr. med. Dirk Peetz
(Adviser)